Ideas

Molecular therapy for TIIDM and obesity-associated metabolic deficits: N-Acetyl Serotonin increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 7/December/2017, 7.13 am
Molecular therapy for TIIDM and obesity-associated metabolic deficits: N-Acetyl Serotonin increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 7/December/2017, 7.13 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite…

read more

Natural product therapy for body weight control, energy homeostasis and TIIDM:  Huperzine A decreases CADM1 and its downstream target genes that promote glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 7/December/2017, 6.18 am
Natural product therapy for body weight control, energy homeostasis and TIIDM:  Huperzine A decreases CADM1 and its downstream target genes that promote glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 7/December/2017, 6.18 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Max Delbrück Center for Molecular Medicine, Berlin, Germany shows that “Regulation of body weight and energy homeostasis by neuronal cell adhesion molecule1.”…

read more

Molecular therapy for body weight control, energy homeostasis and TIIDM: Rosiglitazone(Brand name: Avantia), an anti-hyperglycemic medication,  inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 6/December/2017, 12.24 am
Molecular therapy for body weight control, energy homeostasis and TIIDM: Rosiglitazone(Brand name: Avantia), an anti-hyperglycemic medication,  inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 6/December/2017, 12.24 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator of adipose insulin resistance.”…

read more

Molecular therapy for heart regeneration and repair: Agomelatine (brand names: Valdoxan, Melitor, Thymanax), an antidepressant, increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up regulation of its target gene, 5/December/2017, 11.59 pm
Molecular therapy for heart regeneration and repair: Agomelatine (brand names: Valdoxan, Melitor, Thymanax), an antidepressant, increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up regulation of its target gene, 5/December/2017, 11.59 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, Durham, North Carolina 27708,…

read more

Molecular therapy for Cardiomyopathy: Tetramethylpyrazine nitrone (TBN), a neuroprotective drug candidate for stroke, decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene, 5/December/2017,  11.55 pm
Molecular therapy for Cardiomyopathy: Tetramethylpyrazine nitrone (TBN), a neuroprotective drug candidate for stroke, decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene, 5/December/2017,  11.55 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A recent study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA shows that “Trbp regulates heart function through microRNA-mediated Sox6 repression.” This…

read more

Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Agmatine (4-Aminobutyl guanidine), a neurotransmitter, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down regulation of its target gene, 5/December/2017, 11.51 pm
Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Agmatine (4-Aminobutyl guanidine), a neurotransmitter, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down regulation of its target gene, 5/December/2017, 11.51 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was published, in the 6 April…

read more
Start Typing